Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Daclatasvir (Daklinza) for HCV genotype 3 infection.

The Medical letter on drugs and therapeutics - 12 Oct 2015

Abstract excerpt

Daclatasvir (Daklinza) plus sofosbuvir (Sovaldi) is the first all-oral, interferon- and ribavirin-free drug regimen for treatment of hepatitis C virus genotype 3 infection. This combination is effective and convenient, but it is very expensive.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carbamates
Share to Clinical Trials as Topic
Share to Drug Therapy, Combination
Share to Hepatitis C

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imidazoles

Share to Pyrrolidines

Share to Sofosbuvir

Share to Valine

Source

Identifiers

PMID: 26445205

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Daclatasvir (Daklinza) for HCV genotype 3 infection.PMID 26445205Read ↗

Daclatasvir plus sofosbuvir regimen sheds promising light on future hepatitis C virus genotype 3 therapies.Semantic proximity Read ↗

Dual daclatasvir and sofosbuvir for treatment of genotype 3 chronic hepatitis C virus infection.Semantic proximity Read ↗

All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study.Semantic proximity Read ↗

Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+).Semantic proximity Read ↗

Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme.Semantic proximity Read ↗

Daclatasvir: A NS5A Replication Complex Inhibitor for Hepatitis C Infection.Semantic proximity Read ↗

Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.Semantic proximity Read ↗

Real-world effectiveness of sofosbuvir-based treatment regimens for chronic hepatitis C genotype 3 infection: Results from the multicenter German hepatitis C cohort (GECCO-03).Semantic proximity Read ↗

Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection.Semantic proximity Read ↗

Daclatasvir + sofosbuvir versus standard of care for hepatitis C genotype 3: a matching-adjusted indirect comparison.Semantic proximity Read ↗

Cost-effectiveness of combination daclatasvir-sofosbuvir for treatment of genotype 3 chronic hepatitis C infection in the United States.Semantic proximity Read ↗

Treatment of hepatitis C virus genotype 3-infection.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.